- Home
- LU vs ORIC Comparison
LU vs ORIC Comparison
Compare LU & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | ORIC |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LU | ORIC |
|---|---|---|
| Price | $1.22 | $12.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $2.00 | ★ $19.73 |
| AVG Volume (30 Days) | 786.4K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $7.23 |
| 52 Week High | $4.57 | $14.93 |
Technical Indicators
Market Signals| Indicator | LU | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 35.37 | 41.69 |
| Support Level | $1.20 | $10.67 |
| Resistance Level | $1.45 | $12.57 |
| Average True Range (ATR) | 0.05 | 0.60 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 7.69 | 0.84 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.